Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms

The use of membrane-localizing DOTA-LM3 was beneficial and profited from the short-ranged electrons emitted by terbium-161. Based on these preclinical data, [¹⁶¹Tb]Tb-DOTA-LM3 may outperform the clinically employed [¹⁷⁷Lu]Lu-DOTATOC for the treatment of patients with NENs.